Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients - Trial NCT06092437
Access comprehensive clinical trial information for NCT06092437 through Pure Global AI's free database. This phase not specified trial is sponsored by Zuyderland Medisch Centrum and is currently Recruiting. The study focuses on Heart Failure Acute. Target enrollment is 466 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zuyderland Medisch Centrum
Timeline & Enrollment
N/A
Feb 27, 2023
Feb 27, 2026
Primary Outcome
Hierarchical composite of all-cause mortality, heart failure events and delta quality of life at 90 days follow-up.
Summary
Acutely decompensated heart failure (ADHF) is highly prevalent and has a high (financial)
 burden on the health care system. Treatment often consists of the administration of IV
 decongestive agents. Adequate dosing is difficult due to varying diuretic resistance and
 inadequate parameters to evaluate the response. Urine sodium is a promising biomarker to
 evaluate the diuretic response. It is hypothesized that a tailored, urine sodium guided
 diuretic algorithm will result in faster and more complete decongestion and therefore lead to
 better survival (in terms of mortality and heart failure events) while being non-inferior in
 terms of safety (mainly regression of kidney function).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06092437
Non-Device Trial